CGEM Live signals | Maximize Profits with Getagraph.com

SELL 102771 min ago

@ $17.99

Issued: 14 Feb 2024 @ 15:07

Return: 7.00%

Previous signal: Feb 14 - 14:44

Previous signal: Buy

Return: 1.47 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States...

Stats
Today's Volume	1.27M
Average Volume	551 629
Market Cap	829.01M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.880 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.22
ATR14	$0.0280 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-29	Nguyen Nate	Sell	0	Common Stock
2024-03-29	Nguyen Nate	Sell	0	Common Stock
2024-03-29	Nguyen Nate	Sell	62 500	Stock Option (Right to Buy)
2024-03-29	Nguyen Nate	Sell	26 750	Stock Option (Right to Buy)
2024-03-29	Nguyen Nate	Sell	26 750	Stock Option (Right to Buy)

INSIDER POWER
-16.77
Last 99 transactions
Buy: 3 117 515 \| Sell: 6 664 307

Volume Correlation

Long: 0.15 (neutral)

Short: 0.78 (moderate)

Signal:(76.599) Neutral

Cullinan Oncology, LLC Correlation

10 Most Positive Correlations
METC	0.827
RXRX	0.825
FSTR	0.822
AMTX	0.81
NTNX	0.805
TEAM	0.803
SNAX	0.802

10 Most Negative Correlations
BNIXU	-0.831
PODD	-0.808

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cullinan Oncology, LLC Correlation - Currency/Commodity

-0.03
( neutral )

-0.14
( neutral )

0.00
( neutral )

-0.01
( neutral )

0.69
( moderate )

-0.56
( weak negative )

Cullinan Oncology, LLC Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-310 000 (0.00 %)
EPS:	$-3.69

Q4	2023
Revenue:	$0
Gross Profit:	$-77 000.00 (0.00 %)
EPS:	$-0.560

Q3	2023
Revenue:	$0
Gross Profit:	$-80 000.00 (0.00 %)
EPS:	$-0.920

Q2	2023
Revenue:	$0
Gross Profit:	$-81 000.00 (0.00 %)
EPS:	$-0.810

Financial Reports:

No articles found.

Cullinan Oncology, LLC

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.